Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.
JAMA Neurology 73(6):721 (2016)
The use of anticholinergic (AC) medication is linked to cognitive impairment and an increased risk of dementia. To our knowledge, this is the first study to investigate the association between AC medication use and neuroimaging biomarkers of brain metabolism and atrophy as a proxy for understand...
Quality Improvement in Skilled Nursing Facilities for Residents With Alzheimer's Disease.
American Journal of Alzheimer's Disease and Oth... 31(2):156 (2016)
This report describes a quality improvement continuing medical education activity designed to enhance the recognition and treatment of residents with Alzheimer's disease (AD) or other dementias in skilled-nursing facilities (SNFs).
Charts were compared in 6 areas prior to and following (stages A...
[(11)C]PiB PET in Gerstmann-Sträussler-Scheinker disease.
American journal of nuclear medicine and molecu... 6(1):84 (2016)
Gerstmann-Sträussler-Scheinker Disease (GSS) is a familial neurodegenerative disorder characterized clinically by ataxia, parkinsonism, and dementia, and neuropathologically by deposition of diffuse and amyloid plaques composed of prion protein (PrP). The purpose of this study was to evaluate if...
The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests.
Journal of Alzheimer's Disease 51(4):1145 (2016)
The perception of cognitive decline by individuals and those who know them well ("informants") has been inconsistently associated with objective cognitive performance, but strongly associated with depressive symptoms.
We investigated associations of self-report, informant-report, and discrepancy...
Corrigendum: Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis.
Scientific reports 6:20747 (2016)
Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial.
Neurology 85(22):1937 (2015)
To determine whether raloxifene, a selective estrogen receptor modulator, improves cognitive function compared with placebo in women with Alzheimer disease (AD) and to provide an estimate of cognitive effect.
This pilot study was conducted as a randomized, double-blind, placebo-controlled trial,...
GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.
Brain 138(Pt 10):3076 (2015)
Brain amyloid deposition is thought to be a seminal event in Alzheimer's disease. To identify genes influencing Alzheimer's disease pathogenesis, we performed a genome-wide association study of longitudinal change in brain amyloid burden measured by (18)F-florbetapir PET. A novel association wit...
Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease.
Neurology 85(9):790 (2015)
To investigate the associations of cerebral amyloidosis with concurrent cognitive performance and with longitudinal cognitive decline in asymptomatic and symptomatic stages of autosomal dominant Alzheimer disease (ADAD).
Two hundred sixty-three participants enrolled in the Dominantly Inherited A...
Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.
CNS Neuroscience & Therapeutics 21(6):513 (2015)
To identify factors predicting improvement/stabilization on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and investigate whether early treatment responses can predict long-term outcomes, during a trial of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine ...
Protective variant for hippocampal atrophy identified by whole exome sequencing.
Annals of Neurology 77(3):547 (2015)
We used whole-exome sequencing to identify variants other than APOE associated with the rate of hippocampal atrophy in amnestic mild cognitive impairment. An in-silico predicted missense variant in REST (rs3796529) was found exclusively in subjects with slow hippocampal volume loss and validated...
Factors associated with the onset and persistence of post-lumbar puncture headache.
JAMA Neurology 72(3):325 (2015)
This study assesses factors associated with the most common adverse event following lumbar puncture.
To identify factors associated with the risk, onset, and persistence of post-dural puncture headache (PDPH).
We performed univariate and multivariable analyses of 338 lumbar punctures in the Domi...
Rarity of the Alzheimer disease-protective APP A673T variant in the United States.
JAMA Neurology 72(2):209 (2015)
Recently, a rare variant in the amyloid precursor protein gene (APP) was described in a population from Iceland. This variant, in which alanine is replaced by threonine at position 673 (A673T), appears to protect against late-onset Alzheimer disease (AD). We evaluated the frequency of this varia...
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease.
Alzheimer's Research & Therapy 7(1):23 (2015)
CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses. The CAD106 first-in-human study demonstrated a favorable safety profile and promising antibody response. We investigated long-term safety, tolerability and antibody response aft...
A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.
Alzheimer Disease and Associated Disorders 29(2):110 (2015)
The long-term safety, tolerability, and efficacy of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer disease was evaluated in a 24-week, open-label extension to the double-blind ACTION study. Safety and tolerability, and efficacy on the Alzheimer's Disease Cooperative Study-Activiti...
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Current Alzheimer Research 12(1):53 (2015)
ACTION, a 24-week, prospective, randomized, parallel-group, double-blind study in patients with severe Alzheimer's disease (AD), demonstrated significant efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on the Severe Impairment Battery (SIB) and Alzheimer's Disease Cooperative Stud...
Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.
Nature Communications 6:7247 (2015)
Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n=152) and 3,311 controls, and 67 CBD cases and 439 controls in a replication stage. Ass...
Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis.
Scientific reports 5:16953 (2015)
Adipose stromal cells (ASC) secrete various trophic factors that assist in the protection of neurons in a variety of neuronal death models. In this study, we tested the effects of human ASC conditional medium (ASC-CM) in human amyotrophic lateral sclerosis (ALS) transgenic mouse model expressing...
An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.
Alzheimer's Research & Therapy 7(1):53 (2015)
Amyloid-β (Aβ) has been investigated as a diagnostic biomarker and therapeutic drug target. Recent studies found that cerebrospinal fluid (CSF) Aβ fluctuates over time, including as a diurnal pattern, and increases in absolute concentration with serial collection. It is currently unknown what ef...
Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults.
Journal of Alzheimer's Disease 45(4):1197 (2015)
Depressive symptoms are common in older adults and are particularly prevalent in those with or at elevated risk for dementia. Although the heritability of depression is estimated to be substantial, single nucleotide polymorphism-based genome-wide association studies of depressive symptoms have h...
Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study.
JAMA Neurology 71(11):1394 (2014)
Because APOE locus variants contribute to risk of late-onset Alzheimer disease (LOAD) and to differences in age at onset (AAO), it is important to know whether other established LOAD risk loci also affect AAO in affected participants.
To investigate the effects of known Alzheimer disease risk lo...